I assume that Celphalon are happy with the data given they have taken up options and convertible notes. If that is the case why would the directors recommend the takeover? Why wouldn't they see it through to FDA approval?
CXS Price at posting:
44.0¢ Sentiment: Hold Disclosure: Held